Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer model View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-09-18

AUTHORS

Natividad Gomez-Roman, Fiona McGregor, Nial J. Wheate, Jane A. Plumb

ABSTRACT

BACKGROUND: Ovarian cancer is the most fatal of gynaecological malignancies, usually detected at a late stage with intraperitoneal dissemination. Appropriate preclinical models are needed that recapitulate both the histopathological and molecular features of human ovarian cancer for drug-efficacy analysis. METHODS: Longitudinal studies comparing cisplatin performance either alone or in a novel cisplatin-based delivery-system, cucurbit[7]uril-encapsulated cisplatin (cisplatin@CB[7]) were performed on subcutaneous (s.c.) and intraperitoneal (i.p.) xenografts using the human ovarian cancer cell line A2780 stably expressing the small GTPase Rab25, which allows A2780 intraperitoneal growth; and luciferase, to allow tumour load measurement by non-invasive bioluminescent imaging. RESULTS: Rab25 expression induced cisplatin resistance compared to the parental cell line as assessed by the MTT assay in vitro. These findings did not translate in vivo, where cisplatin resistance was determined by the microenvironment. Subcutaneous xenografts of either parental A2780 or cisplatin-resistant Rab25-expressing A2780 cells presented similar responses to cisplatin treatment. In contrast, increased cisplatin resistance was only detected in i.p. tumours. Treatment of the cisplatin-resistant i.p. model with the novel cisplatin@CB[7] delivery system resulted in a substantial reduction of i.p. tumour load and increased necrosis. CONCLUSIONS: Poor clinical performance of novel chemotherapeutics might reflect inappropriate preclinical models. Here we present an ovarian i.p. model that recapitulates the histopathological and chemoresistant features of the clinical disease. In addition, we demonstrate that the novel cisplatin-delivery system, cisplatin@CB[7] may have utility in the treatment of drug-resistant ovarian human cancers. More... »

PAGES

62

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13048-015-0189-4

DOI

http://dx.doi.org/10.1186/s13048-015-0189-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1038834089

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26384969


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capsules", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heterografts", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice, Nude", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ovarian Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peritoneal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation, Heterologous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Suppressor Protein p53", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institute of Cancer Sciences, Wolfson Wohl Translational Cancer Research Centre, University of Glasgow, Bearsden, Garscube Estate, Glasgow, G61 1QH, Scotland UK", 
          "id": "http://www.grid.ac/institutes/grid.8756.c", 
          "name": [
            "Institute of Cancer Sciences, Wolfson Wohl Translational Cancer Research Centre, University of Glasgow, Bearsden, Garscube Estate, Glasgow, G61 1QH, Scotland UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gomez-Roman", 
        "givenName": "Natividad", 
        "id": "sg:person.01263322622.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263322622.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Cancer Sciences, Wolfson Wohl Translational Cancer Research Centre, University of Glasgow, Bearsden, Garscube Estate, Glasgow, G61 1QH, Scotland UK", 
          "id": "http://www.grid.ac/institutes/grid.8756.c", 
          "name": [
            "Institute of Cancer Sciences, Wolfson Wohl Translational Cancer Research Centre, University of Glasgow, Bearsden, Garscube Estate, Glasgow, G61 1QH, Scotland UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McGregor", 
        "givenName": "Fiona", 
        "id": "sg:person.01263251021.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263251021.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Pharmacy, The University of Sydney, Sydney, NSW 2006 Australia", 
          "id": "http://www.grid.ac/institutes/grid.1013.3", 
          "name": [
            "Faculty of Pharmacy, The University of Sydney, Sydney, NSW 2006 Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wheate", 
        "givenName": "Nial J.", 
        "id": "sg:person.01137526740.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137526740.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Cancer Sciences, Wolfson Wohl Translational Cancer Research Centre, University of Glasgow, Bearsden, Garscube Estate, Glasgow, G61 1QH, Scotland UK", 
          "id": "http://www.grid.ac/institutes/grid.8756.c", 
          "name": [
            "Institute of Cancer Sciences, Wolfson Wohl Translational Cancer Research Centre, University of Glasgow, Bearsden, Garscube Estate, Glasgow, G61 1QH, Scotland UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Plumb", 
        "givenName": "Jane A.", 
        "id": "sg:person.01131730531.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01131730531.28"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1471-2342-8-16", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041063545", 
          "https://doi.org/10.1186/1471-2342-8-16"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm1125", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013191922", 
          "https://doi.org/10.1038/nm1125"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nprot.2007.25", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027407970", 
          "https://doi.org/10.1038/nprot.2007.25"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm1173", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035826997", 
          "https://doi.org/10.1038/nm1173"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7827-1-67", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038488062", 
          "https://doi.org/10.1186/1477-7827-1-67"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1054/bjoc.2000.1487", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004163844", 
          "https://doi.org/10.1054/bjoc.2000.1487"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-09-18", 
    "datePublishedReg": "2015-09-18", 
    "description": "BACKGROUND: Ovarian cancer is the most fatal of gynaecological malignancies, usually detected at a late stage with intraperitoneal dissemination. Appropriate preclinical models are needed that recapitulate both the histopathological and molecular features of human ovarian cancer for drug-efficacy analysis.\nMETHODS: Longitudinal studies comparing cisplatin performance either alone or in a novel cisplatin-based delivery-system, cucurbit[7]uril-encapsulated cisplatin (cisplatin@CB[7]) were performed on subcutaneous (s.c.) and intraperitoneal (i.p.) xenografts using the human ovarian cancer cell line A2780 stably expressing the small GTPase Rab25, which allows A2780 intraperitoneal growth; and luciferase, to allow tumour load measurement by non-invasive bioluminescent imaging.\nRESULTS: Rab25 expression induced cisplatin resistance compared to the parental cell line as assessed by the MTT assay in vitro. These findings did not translate in vivo, where cisplatin resistance was determined by the microenvironment. Subcutaneous xenografts of either parental A2780 or cisplatin-resistant Rab25-expressing A2780 cells presented similar responses to cisplatin treatment. In contrast, increased cisplatin resistance was only detected in i.p. tumours. Treatment of the cisplatin-resistant i.p. model with the novel cisplatin@CB[7] delivery system resulted in a substantial reduction of i.p. tumour load and increased necrosis.\nCONCLUSIONS: Poor clinical performance of novel chemotherapeutics might reflect inappropriate preclinical models. Here we present an ovarian i.p. model that recapitulates the histopathological and chemoresistant features of the clinical disease. In addition, we demonstrate that the novel cisplatin-delivery system, cisplatin@CB[7] may have utility in the treatment of drug-resistant ovarian human cancers.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s13048-015-0189-4", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1040071", 
        "issn": [
          "1757-2215"
        ], 
        "name": "Journal of Ovarian Research", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "cisplatin resistance", 
      "ovarian cancer", 
      "preclinical models", 
      "non-invasive bioluminescent", 
      "ovarian cancer cell line A2780", 
      "ovarian cancer model", 
      "human ovarian cancer", 
      "cancer cell line A2780", 
      "appropriate preclinical models", 
      "human ovarian cancer cell line A2780", 
      "cell line A2780", 
      "poor clinical performance", 
      "drug efficacy analysis", 
      "gynaecological malignancies", 
      "tumor load", 
      "small GTPase Rab25", 
      "subcutaneous xenografts", 
      "clinical disease", 
      "intraperitoneal dissemination", 
      "intraperitoneal xenografts", 
      "parental cell line", 
      "cancer model", 
      "intraperitoneal growth", 
      "Rab25 expression", 
      "parental A2780", 
      "chemoresistant features", 
      "A2780 cells", 
      "Rab25 overexpression", 
      "clinical performance", 
      "cancer", 
      "human cancers", 
      "novel chemotherapeutics", 
      "longitudinal study", 
      "cell lines", 
      "xenografts", 
      "molecular features", 
      "treatment", 
      "cisplatin", 
      "cisplatin delivery system", 
      "A2780", 
      "similar responses", 
      "delivery system", 
      "Rab25", 
      "malignancy", 
      "later stages", 
      "necrosis", 
      "disease", 
      "load measurements", 
      "substantial reduction", 
      "resistance", 
      "chemotherapeutics", 
      "vivo", 
      "MTT", 
      "microenvironment", 
      "overexpression", 
      "bioluminescent", 
      "cells", 
      "expression", 
      "findings", 
      "dissemination", 
      "luciferase", 
      "response", 
      "study", 
      "contrast", 
      "reduction", 
      "utility", 
      "features", 
      "stage", 
      "addition", 
      "model", 
      "lines", 
      "analysis", 
      "growth", 
      "system", 
      "measurements", 
      "load", 
      "performance", 
      "cucurbits", 
      "cisplatin performance", 
      "line A2780", 
      "GTPase Rab25", 
      "A2780 intraperitoneal growth", 
      "tumour load measurement", 
      "cisplatin-resistant Rab25", 
      "inappropriate preclinical models", 
      "novel cisplatin-delivery system", 
      "drug-resistant ovarian human cancers", 
      "ovarian human cancers", 
      "intraperitoneal ovarian cancer model"
    ], 
    "name": "Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer model", 
    "pagination": "62", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1038834089"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13048-015-0189-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26384969"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13048-015-0189-4", 
      "https://app.dimensions.ai/details/publication/pub.1038834089"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_676.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s13048-015-0189-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13048-015-0189-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13048-015-0189-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13048-015-0189-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13048-015-0189-4'


 

This table displays all metadata directly associated to this object as RDF triples.

266 TRIPLES      22 PREDICATES      138 URIs      124 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13048-015-0189-4 schema:about N4ab023fabcaf464c8dd28e12ab726bb0
2 N4ec6b70d67d34460bff69475288cece4
3 N508b7148a6794400835be0058039fc61
4 N516e5f9718bd4eb6851375af099c930c
5 N6531fb8d23b8448099e0321646ca9464
6 N7a08f7fcc55f49868178eb022ed30756
7 N7f0421730b0c4e19b918a2a46ea1a6cc
8 N858aaad3db734c28ad2be40bdaa2f8e3
9 Na538682f1d404389827b36c8f36e85a9
10 Na56d5fe4d7c449b59eca7435b40fb8dd
11 Nb1300133449c48ccac343a4d831fca32
12 Ncb9b648a287f42c5b6cd49c750907770
13 Nd2477cf56b7643f081ad40409ac766ca
14 Nd46af896d1044d82821d827681aa72e0
15 Ndb22e22af2d84ca7871380204151f839
16 Ne3c024db16424f8d99ef9ce7ae1e4537
17 Nf0a434bcb8e14b0781d698ae2631aa3f
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author Na658f1af2e1f4f4db10a029ff8b94a09
21 schema:citation sg:pub.10.1038/nm1125
22 sg:pub.10.1038/nm1173
23 sg:pub.10.1038/nprot.2007.25
24 sg:pub.10.1054/bjoc.2000.1487
25 sg:pub.10.1186/1471-2342-8-16
26 sg:pub.10.1186/1477-7827-1-67
27 schema:datePublished 2015-09-18
28 schema:datePublishedReg 2015-09-18
29 schema:description BACKGROUND: Ovarian cancer is the most fatal of gynaecological malignancies, usually detected at a late stage with intraperitoneal dissemination. Appropriate preclinical models are needed that recapitulate both the histopathological and molecular features of human ovarian cancer for drug-efficacy analysis. METHODS: Longitudinal studies comparing cisplatin performance either alone or in a novel cisplatin-based delivery-system, cucurbit[7]uril-encapsulated cisplatin (cisplatin@CB[7]) were performed on subcutaneous (s.c.) and intraperitoneal (i.p.) xenografts using the human ovarian cancer cell line A2780 stably expressing the small GTPase Rab25, which allows A2780 intraperitoneal growth; and luciferase, to allow tumour load measurement by non-invasive bioluminescent imaging. RESULTS: Rab25 expression induced cisplatin resistance compared to the parental cell line as assessed by the MTT assay in vitro. These findings did not translate in vivo, where cisplatin resistance was determined by the microenvironment. Subcutaneous xenografts of either parental A2780 or cisplatin-resistant Rab25-expressing A2780 cells presented similar responses to cisplatin treatment. In contrast, increased cisplatin resistance was only detected in i.p. tumours. Treatment of the cisplatin-resistant i.p. model with the novel cisplatin@CB[7] delivery system resulted in a substantial reduction of i.p. tumour load and increased necrosis. CONCLUSIONS: Poor clinical performance of novel chemotherapeutics might reflect inappropriate preclinical models. Here we present an ovarian i.p. model that recapitulates the histopathological and chemoresistant features of the clinical disease. In addition, we demonstrate that the novel cisplatin-delivery system, cisplatin@CB[7] may have utility in the treatment of drug-resistant ovarian human cancers.
30 schema:genre article
31 schema:inLanguage en
32 schema:isAccessibleForFree true
33 schema:isPartOf N54f07dff77f54ddcb114c004905b43b7
34 Nd6dbb76174424118938a3781e273c579
35 sg:journal.1040071
36 schema:keywords A2780
37 A2780 cells
38 A2780 intraperitoneal growth
39 GTPase Rab25
40 MTT
41 Rab25
42 Rab25 expression
43 Rab25 overexpression
44 addition
45 analysis
46 appropriate preclinical models
47 bioluminescent
48 cancer
49 cancer cell line A2780
50 cancer model
51 cell line A2780
52 cell lines
53 cells
54 chemoresistant features
55 chemotherapeutics
56 cisplatin
57 cisplatin delivery system
58 cisplatin performance
59 cisplatin resistance
60 cisplatin-resistant Rab25
61 clinical disease
62 clinical performance
63 contrast
64 cucurbits
65 delivery system
66 disease
67 dissemination
68 drug efficacy analysis
69 drug-resistant ovarian human cancers
70 expression
71 features
72 findings
73 growth
74 gynaecological malignancies
75 human cancers
76 human ovarian cancer
77 human ovarian cancer cell line A2780
78 inappropriate preclinical models
79 intraperitoneal dissemination
80 intraperitoneal growth
81 intraperitoneal ovarian cancer model
82 intraperitoneal xenografts
83 later stages
84 line A2780
85 lines
86 load
87 load measurements
88 longitudinal study
89 luciferase
90 malignancy
91 measurements
92 microenvironment
93 model
94 molecular features
95 necrosis
96 non-invasive bioluminescent
97 novel chemotherapeutics
98 novel cisplatin-delivery system
99 ovarian cancer
100 ovarian cancer cell line A2780
101 ovarian cancer model
102 ovarian human cancers
103 overexpression
104 parental A2780
105 parental cell line
106 performance
107 poor clinical performance
108 preclinical models
109 reduction
110 resistance
111 response
112 similar responses
113 small GTPase Rab25
114 stage
115 study
116 subcutaneous xenografts
117 substantial reduction
118 system
119 treatment
120 tumor load
121 tumour load measurement
122 utility
123 vivo
124 xenografts
125 schema:name Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer model
126 schema:pagination 62
127 schema:productId N4739c1ccf8eb48e6b58ef873946c70a7
128 N73faa871fe3f42388b9e00fb43a8c34e
129 Ne88ef6fe21ec449c87e2e1d28f7fe6b3
130 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038834089
131 https://doi.org/10.1186/s13048-015-0189-4
132 schema:sdDatePublished 2021-12-01T19:34
133 schema:sdLicense https://scigraph.springernature.com/explorer/license/
134 schema:sdPublisher N414e59b0722b451d80fa36e0f450febf
135 schema:url https://doi.org/10.1186/s13048-015-0189-4
136 sgo:license sg:explorer/license/
137 sgo:sdDataset articles
138 rdf:type schema:ScholarlyArticle
139 N414e59b0722b451d80fa36e0f450febf schema:name Springer Nature - SN SciGraph project
140 rdf:type schema:Organization
141 N4739c1ccf8eb48e6b58ef873946c70a7 schema:name pubmed_id
142 schema:value 26384969
143 rdf:type schema:PropertyValue
144 N4ab023fabcaf464c8dd28e12ab726bb0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Antineoplastic Agents
146 rdf:type schema:DefinedTerm
147 N4ec6b70d67d34460bff69475288cece4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Carcinoma
149 rdf:type schema:DefinedTerm
150 N508b7148a6794400835be0058039fc61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Proteins
152 rdf:type schema:DefinedTerm
153 N516e5f9718bd4eb6851375af099c930c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Animals
155 rdf:type schema:DefinedTerm
156 N54f07dff77f54ddcb114c004905b43b7 schema:issueNumber 1
157 rdf:type schema:PublicationIssue
158 N6531fb8d23b8448099e0321646ca9464 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Injections
160 rdf:type schema:DefinedTerm
161 N73faa871fe3f42388b9e00fb43a8c34e schema:name doi
162 schema:value 10.1186/s13048-015-0189-4
163 rdf:type schema:PropertyValue
164 N7731fb540ff84a4ea32237faf323b96f rdf:first sg:person.01137526740.20
165 rdf:rest Ncf835daf78ef4924b709792af30db7eb
166 N7a08f7fcc55f49868178eb022ed30756 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Tumor Suppressor Protein p53
168 rdf:type schema:DefinedTerm
169 N7f0421730b0c4e19b918a2a46ea1a6cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Capsules
171 rdf:type schema:DefinedTerm
172 N858aaad3db734c28ad2be40bdaa2f8e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Female
174 rdf:type schema:DefinedTerm
175 Na538682f1d404389827b36c8f36e85a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Transplantation, Heterologous
177 rdf:type schema:DefinedTerm
178 Na56d5fe4d7c449b59eca7435b40fb8dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Neoplasm Transplantation
180 rdf:type schema:DefinedTerm
181 Na658f1af2e1f4f4db10a029ff8b94a09 rdf:first sg:person.01263322622.24
182 rdf:rest Nadf27282f7ca4e99844e7c03d292159b
183 Nadf27282f7ca4e99844e7c03d292159b rdf:first sg:person.01263251021.18
184 rdf:rest N7731fb540ff84a4ea32237faf323b96f
185 Nb1300133449c48ccac343a4d831fca32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Heterografts
187 rdf:type schema:DefinedTerm
188 Ncb9b648a287f42c5b6cd49c750907770 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Ovarian Neoplasms
190 rdf:type schema:DefinedTerm
191 Ncf835daf78ef4924b709792af30db7eb rdf:first sg:person.01131730531.28
192 rdf:rest rdf:nil
193 Nd2477cf56b7643f081ad40409ac766ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Drug Resistance, Neoplasm
195 rdf:type schema:DefinedTerm
196 Nd46af896d1044d82821d827681aa72e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Mice, Nude
198 rdf:type schema:DefinedTerm
199 Nd6dbb76174424118938a3781e273c579 schema:volumeNumber 8
200 rdf:type schema:PublicationVolume
201 Ndb22e22af2d84ca7871380204151f839 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Peritoneal Neoplasms
203 rdf:type schema:DefinedTerm
204 Ne3c024db16424f8d99ef9ce7ae1e4537 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Cisplatin
206 rdf:type schema:DefinedTerm
207 Ne88ef6fe21ec449c87e2e1d28f7fe6b3 schema:name dimensions_id
208 schema:value pub.1038834089
209 rdf:type schema:PropertyValue
210 Nf0a434bcb8e14b0781d698ae2631aa3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Cell Line, Tumor
212 rdf:type schema:DefinedTerm
213 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
214 schema:name Medical and Health Sciences
215 rdf:type schema:DefinedTerm
216 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
217 schema:name Oncology and Carcinogenesis
218 rdf:type schema:DefinedTerm
219 sg:journal.1040071 schema:issn 1757-2215
220 schema:name Journal of Ovarian Research
221 schema:publisher Springer Nature
222 rdf:type schema:Periodical
223 sg:person.01131730531.28 schema:affiliation grid-institutes:grid.8756.c
224 schema:familyName Plumb
225 schema:givenName Jane A.
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01131730531.28
227 rdf:type schema:Person
228 sg:person.01137526740.20 schema:affiliation grid-institutes:grid.1013.3
229 schema:familyName Wheate
230 schema:givenName Nial J.
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137526740.20
232 rdf:type schema:Person
233 sg:person.01263251021.18 schema:affiliation grid-institutes:grid.8756.c
234 schema:familyName McGregor
235 schema:givenName Fiona
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263251021.18
237 rdf:type schema:Person
238 sg:person.01263322622.24 schema:affiliation grid-institutes:grid.8756.c
239 schema:familyName Gomez-Roman
240 schema:givenName Natividad
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263322622.24
242 rdf:type schema:Person
243 sg:pub.10.1038/nm1125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013191922
244 https://doi.org/10.1038/nm1125
245 rdf:type schema:CreativeWork
246 sg:pub.10.1038/nm1173 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035826997
247 https://doi.org/10.1038/nm1173
248 rdf:type schema:CreativeWork
249 sg:pub.10.1038/nprot.2007.25 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027407970
250 https://doi.org/10.1038/nprot.2007.25
251 rdf:type schema:CreativeWork
252 sg:pub.10.1054/bjoc.2000.1487 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004163844
253 https://doi.org/10.1054/bjoc.2000.1487
254 rdf:type schema:CreativeWork
255 sg:pub.10.1186/1471-2342-8-16 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041063545
256 https://doi.org/10.1186/1471-2342-8-16
257 rdf:type schema:CreativeWork
258 sg:pub.10.1186/1477-7827-1-67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038488062
259 https://doi.org/10.1186/1477-7827-1-67
260 rdf:type schema:CreativeWork
261 grid-institutes:grid.1013.3 schema:alternateName Faculty of Pharmacy, The University of Sydney, Sydney, NSW 2006 Australia
262 schema:name Faculty of Pharmacy, The University of Sydney, Sydney, NSW 2006 Australia
263 rdf:type schema:Organization
264 grid-institutes:grid.8756.c schema:alternateName Institute of Cancer Sciences, Wolfson Wohl Translational Cancer Research Centre, University of Glasgow, Bearsden, Garscube Estate, Glasgow, G61 1QH, Scotland UK
265 schema:name Institute of Cancer Sciences, Wolfson Wohl Translational Cancer Research Centre, University of Glasgow, Bearsden, Garscube Estate, Glasgow, G61 1QH, Scotland UK
266 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...